Literature DB >> 11029377

Antisense oligonucleotides to NF-kappaB improve survival in bleomycin-induced pneumopathy of the mouse.

X Y Zhang1, S Shimura, T Masuda, H Saitoh, K Shirato.   

Abstract

We examined the effect of antisense oligonucleotides to the p65 subunit of NF-kappaB on the survival of bleomycin (BLM)-induced pneumonitis in C57BL/6 mice (female, 8 wk of age, 17 to 20 g body weight). Fifty-three percent and all control mice died within 6 to 9 d after intravenous administration of 150 and 300 mg/kg BLM alone, respectively. The intravenous administration of the antisense oligonucleotides (900 microgram/animal dissolved in 200 microliter saline, 6 h before and 5 d after BLM administration) significantly improved the survival rate to 100 and 40% in 150- and 300-mg/kg-treated animals, respectively. The antisense oligonucleotides also significantly improved the loss of body weight, the increase in lung hydroxyproline, and histologic changes by BLM, whereas the antisense oligonucleotides themselves did not produce any significant changes in the behavior or lung histology. Both peripheral blood monocytes and alveolar macrophages were confirmed to contain large amounts of intracellular antisense oligonucleotides after BLM injection by FITC-labeled fluorescent microscopy. Further, Western blotting confirmed the inhibition of NF-kappaB in macrophages by the antisense oligonucleotides. These findings suggest that the antisense oligonucleotides are incorporated into activated alveolar macrophages and ameleriorate the lung injury and pneumonitis/fibrosis, thereby improving the survival of BLM-induced pneumopathy in mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029377     DOI: 10.1164/ajrccm.162.4.9908093

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats.

Authors:  A Serrano-Mollar; D Closa; N Prats; S Blesa; M Martinez-Losa; J Cortijo; J M Estrela; E J Morcillo; O Bulbena
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

2.  Discoidin domain receptor 1 contributes to the survival of lung fibroblast in idiopathic pulmonary fibrosis.

Authors:  Wataru Matsuyama; Masaki Watanabe; Yuko Shirahama; Hideo Mitsuyama; Ikkou Higashimoto; Mitsuhiro Osame; Kimiyoshi Arimura
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

Review 3.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

Review 4.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy.

Authors:  Mehrnaz Gharaee-Kermani; Margaret R Gyetko; Biao Hu; Sem H Phan
Journal:  Pharm Res       Date:  2007-03-01       Impact factor: 4.580

5.  Antisense oligonucleotide inhibition of heat shock protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in rats.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Shigekiyo Matsumoto; Takayuki Noguchi
Journal:  Respir Res       Date:  2007-05-15

6.  Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.

Authors:  Yuko Waseda; Masahide Yasui; Yoriko Nishizawa; Kanako Inuzuka; Hazuki Takato; Yukari Ichikawa; Atsuro Tagami; Masaki Fujimura; Shinji Nakao
Journal:  Respir Res       Date:  2008-05-23

7.  Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Nana Song; Jun Liu; Saad Shaheen; Lei Du; Mary Proctor; Jesse Roman; Jerry Yu
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

8.  The effect of NF-κB antisense oligonucleotide on transdifferentiation of fibroblast in lung tissue of mice injured by bleomycin.

Authors:  Yan Zhou; Xiaoye Zhang; Mingqi Tan; Rui Zheng; Li Zhao
Journal:  Mol Biol Rep       Date:  2014-03-02       Impact factor: 2.316

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.